Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9234
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFarina, N Ken
dc.contributor.authorJohnston, Colin Ien
dc.contributor.authorBurrell, Louise Men
dc.date.accessioned2015-05-15T22:14:54Z
dc.date.available2015-05-15T22:14:54Z
dc.date.issued2000-06-01en
dc.identifier.citationJournal of Hypertension; 18(6): 749-55en
dc.identifier.govdoc10872560en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9234en
dc.description.abstractThe major advantage of dual inhibitors of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) is their ability to lower blood pressure irrespective of renin or volume status. The aim of this study was to determine whether dual NEP/ACE inhibition produces different effects on cardiovascular structure and fibrosis, hormonal parameters and inhibition of tissue enzymes compared with selective inhibition of ACE and NEP in the spontaneously hypertensive rat (SHR).Male SHRs received the dual NEP/ACE inhibitor (S21402, 100 mg/kg per day), the ACE inhibitor (captopril, 50 mg/kg per day), the NEP inhibitor (SCH42495, 60 mg/kg per day) or vehicle for 2 weeks.S21402 produced equivalent blood pressure lowering effects to captopril (vehicle, 220 +/- 1 mmHg; S21402, 189 +/- 2 mmHg; captopril, 187 +/- 3 mmHg), but was a more effective antihypertensive agent than SCH42495 (214 +/- 2 mmHg, P< 0.01). All treatments reduced left ventricular mass (P< 0.05) and cardiac fibrosis (P< 0.01). S21402 inhibited renal NEP and ACE (P< 0.01), SCH42495 inhibited renal NEP (P < 0.01), and captopril inhibited renal ACE (P< 0.01). Captopril and S21402 increased plasma renin activity (P< 0.05), but the rise with S21402 was attenuated compared with that caused by captopril (P< 0.01). All treatments reduced plasma aldosterone levels (P< 0.01), and NEP inhibition with SCH42495 and S21402 increased plasma atrial natriuretic peptide (ANP; P< 0.05).These results indicate that selective NEP inhibition has major benefits in the regression of cardiac hypertrophy and reduction of fibrosis but has limited antihypertensive effects. The dual NEP/ACE inhibitor S21402 offered no advantage over the selective ACE inhibitor in terms of blood pressure reduction, or attenuation of cardiac hypertrophy and fibrosis, but did increase plasma ANP and blunted the reactive rise in renin with ACE inhibition. Further studies are needed to determine whether more complete blockade of the renin-angiotensin system with dual NEP/ACE inhibition results in additional benefits in terms of morbidity and mortality in cardiovascular disease.en
dc.language.isoenen
dc.subject.otherAldosterone.blooden
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.pharmacologyen
dc.subject.otherAnimalsen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCaptopril.pharmacologyen
dc.subject.otherCardiomegaly.etiology.metabolism.pathologyen
dc.subject.otherEnzyme Inhibitors.pharmacologyen
dc.subject.otherFibrosisen
dc.subject.otherHypertension.blood.complications.physiopathologyen
dc.subject.otherKidney.metabolismen
dc.subject.otherMaleen
dc.subject.otherMethionine.analogs & derivatives.pharmacologyen
dc.subject.otherMyocardium.metabolism.pathologyen
dc.subject.otherNeprilysin.antagonists & inhibitors.metabolismen
dc.subject.otherOrgan Size.drug effectsen
dc.subject.otherPropionates.pharmacologyen
dc.subject.otherProtease Inhibitors.pharmacologyen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred SHRen
dc.subject.otherRenin.blooden
dc.subject.otherSulfhydryl Compounds.pharmacologyen
dc.titleReversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Hypertensionen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.description.pages749-55en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/10872560en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.